Gelonghui October 31st news | beijing tiantan biological products corporation (600161.SH) announced that the "Human Prothrombin Complex" developed by its subsidiary guizhou biological pharmaceutical co., ltd. of China National Pharmaceutical Group has completed the clinical ethical review, pre-clinical recruitment preparation, and officially launched phase III clinical trials in recent days.
天坛生物(600161.SH)：研制的“人凝血酶原复合物” 已完成临床伦理审查、临床入组前准备等工作，于近日正式开展Ⅲ期临床试验
Beijing Tiantan Biological Products Corporation (600161.SH): The "Human Prothrombin Complex" developed has completed clinical ethical review, pre-clinical preparation for inclusion and other work, and officially started phase III clinical trials recently.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated